The Migraine Relief Center Blog

Here’s the latest from the Migraine Relief Center

Keep up with the doctors, patients, treatments—and results—from all our locations.

Can Blue Light Blocking Glasses Prevent Migraines?

By Migraine Relief Center on February 26, 2020

Blue light blocking glasses, or computer glasses as they’re sometimes known, are being marketed as a preventative to eyestrain, headaches, and long-term retinal damage. However, science doesn’t necessarily back up those claims.

Read More

How You Can Help Someone With Migraines

By Migraine Relief Center on February 13, 2020

Over 37 million people in the United States suffer from chronic migraines. Chances are you know someone who is disabled several times a month with excruciating head pain. If you have never had a migraine yourself, it can be easy to dismiss it as another headache until you see a loved one sidelined from life.

Read More

Why Is Headache Misdiagnosed In Women?

By Migraine Relief Center on December 31, 2019

The misdiagnosis of migraine is common. Around half of people presenting with headache pain are not diagnosed correctly as to its cause. So, there is already an issue present that can become more challenging for women.

Read More

A Review: Three Studies of the Effects of Cannabis on Migraines

By Migraine Relief Center on December 9, 2019

While the popularity of cannabidiol (CBD) continues to soar, there are still few studies available with data to support its use. Now that industrial hemp farming is legal, studies of hemp oil and CBD on migraines may become more available. Confounding some of the efforts is the fact that, while CBD is legal at the federal level, it is still illegal in some states. However, the trend appears to be toward the legalization of CBD in certain forms.

Read More

Digital Media and Migraines - The New Trigger?

By Migraine Relief Center on November 25, 2019

Up to 90% of migraineurs are sensitive to light, either before, during, or after a migraine attack.  That light sensitivity can be enough to trigger a migraine, and most digital media is light-based. So it makes sense that the use of digital devices and consuming digital media could trigger migraines in susceptible people. 

Read More

FDA Approval of Reyvow (rasmitidan) for Migraines

By Migraine Relief Center on November 11, 2019

People suffering from acute migraines will soon have another rescue medication at their disposal - The FDA approved Reyvow (lasmiditan hemisuccinate). The US Drug Enforcement Administration (DEA) has 90 days to review the drug to determine if it will be classified as a controlled substance. Once that three-month period is complete, the maker, Eli Lilly, and Company expect it to be available at retail pharmacies.

Read More

Ketamine and Migraines – A Wonder Drug?

By Migraine Relief Center on October 25, 2019

When a migraine doesn't respond to any other treatment, ketamine may offer relief. Operating differently than opioids, non-steroidal anti-inflammatories, and triptans, ketamine is increasingly available to treat chronic pain, migraine, and other health issues.

Read More

A Review of Electrical Nerve Stimulation

By Migraine Relief Center on October 11, 2019

Within the past decade, electrical nerve stimulation has been introduced as a potential non-drug treatment for individuals suffering migraines or cluster headaches. The approach varies slightly between techniques, and depending on the method, can be invasive or non-invasive.

Read More

Do You Have Episodic Migraines?

By Migraine Relief Center on September 30, 2019

Migraines come in several flavors, but one of the primary classifications is that of episodic migraine. Episodic migraines differ from chronic migraine disorder and may respond better to some treatments than chronic migraines.

Read More

What Are the Risks of Opioid Use for Migraineurs in This Age of Crisis?

By Migraine Relief Center on August 21, 2019

“Given the opioid epidemic in the U.S. and the high prevalence of opioid use in migraine patients shown in our study, especially those with chronic migraine, our results suggest that improved management of treatment is needed to optimize care.” - Justin S. Yu, PharmS, Allergan

Read More